Tag: ARDS
Precision Medicine in ARDS
Acute respiratory distress syndrome (ARDS) is a devastating critical illness that can be triggered by a wide range of insults and remains associated with a high mortality of around 40%. The search for targeted treatment for... read more
Early Outcomes After Lung Transplantation for Severe COVID-19
The findings from our report show that lung transplantation is the only option for survival in some patients with severe, unresolving COVID-19-associated ARDS, and that the procedure can be done successfully, with good early... read more
Bodily Pain in Survivors of ARDS
Nearly half of acute respiratory distress syndrome (ARDS) survivors reported bodily pain at 6- and 12-month follow-up; one-third reported pain at both time points. Pre-ARDS unemployment, smoking history, and in-ICU opioid... read more
New Therapy Could Protect Lung Function in COVID-19 Patients
There is an urgent need for new drugs for ARDS patients, including those with COVID-19. ARDS in influenza-infected mice is associated with reduced levels of liponucleotides (essential precursors for de novo phospholipid synthesis)... read more
Trend and Pattern of 100 ARDS Patients Teferred for VV ECMO Treatment
Referral to specialized center for venovenous (VV) ECMO treatment should be considered expeditiously in case of refractory ARDS, which is often lethal. Transport of unstable patients, although challenging, is feasible and... read more
Ultrasound Grayscale Analysis in ARDS COVID-19
Recent evidence regarding the novel coronavirus disease 2019 (COVID19) is growing in describing the characteristics of this disease, with main focus on lung morphology. Few data are available regarding the peripheral and... read more
Promoting Evidence-Based Practice in ARDS
There is a dearth of literature addressing interventions to improve implementation of evidence-based practices in acute respiratory distress syndrome (ARDS). Existing interventions to improve clinician knowledge and facilitate... read more
Remestemcel-L reduces ARDS mortality in those under 65 years old
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone. The data shows remestemcel-L reduced... read more
Prone Positioning in Spontaneously Breathing Subjects With Moderate or Severe ARDS During Invasive Ventilation
In a retrospective analysis of consecutive intubated subjects with moderate or severe ARDS, related or not to COVID-19, spontaneous breathing during prone positioning (PP) was well tolerated and achieved significant improvement... read more
Decreased Mortality in ARDS Patients Treated with Corticosteroids
The use of glucocorticoids might result in reduced mortality in patients with ARDS. Glucocorticoids might be recommended as an adjunct to standard care for ARDS; however, the optimal dose and duration of steroid therapy remains... read more
Expiratory Flow Limitation During Mechanical Ventilation
Expiratory flow limitation (EFL) is present when the flow cannot rise despite an increase in the expiratory driving pressure. The mechanisms of EFL are debated but are believed to be related to the collapsibility of small... read more
Cardiac Markers Implication in Risk-stratification and Management for COVID-19 Patients
COVID-19 patients with pre-existing coronary artery disease represented a higher abnormal percentage of cardiac markers, accompanied by high mortality and ICU admission rate. BNP together with hs-TNI, α- HBDH, CK-MB and... read more
Massive Alveolar Hemorrhage Presenting During the COVID-19 Pandemic
The coronavirus disease (COVID-19) pandemic has challenged healthcare systems and has resulted in complex diagnostic processes for patients with non-COVID-19 pathology. Here, we demonstrate a case of massive alveolar... read more
90 Day Outcomes of COVID-19 Patients in European ICUs
This communication delineates outcomes in COVID-19 patients in the context of ARDS severity, ventilatory management, and variables associated with mortality on a 90-day follow-up for subgroups of patients after ICU admission.... read more
